# India bars routine stem cell therapy for limb ischemia, chronic wounds 2026-08-19T20:13:31+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet The health ministry has issued strict guidelines barring the routine clinical use of stem cell therapy for critical limb ischemia and chronic wounds, permitting it only within authorised research trials. Officials cited 'rampant use of this experimental therapy despite limited knowledge of its safety and efficacy' and said there is little evidence of clinical benefits. A multidisciplinary panel reviewed randomised controlled trials and found 'very low certainty' of benefit for both conditions. For critical limb ischemia, the ministry noted a non-significant reduction in major amputations and no meaningful advantage in ulcer healing, pain-free walking distance or mortality. An identical recommendation applies to chronic wounds from diabetes, venous insufficiency or leprosy. Trials using minimally manipulated cells require ethics committee approval and cell counts, trials with more than minimal manipulation need additional clearance from the Central Drugs Standard Control Organization. India's regenerative medicine market, including stem cell therapy, was valued at Rs 7,641 crore in 2024 and is projected to reach Rs 4.33 trillion by 2033. ## Indian Opinion Analysis The new guidelines close a regulatory gap that allowed unapproved stem cell clinics to market expensive treatments with weak evidence. India had no national standard for such therapies in microvascular conditions, leaving patients vulnerable to exploitation. The government's intervention follows similar cautionary steps by the US FDA and the European Medicines Agency, which also restrict stem cell use to trials for these indications. The real test will be enforcement: India has over 200 registered stem cell clinics, and the CDSCO's capacity to monitor trials remains limited. Watch for the first instance of action against a non-compliant clinic as the signal of how serious the clampdown will be. ## Coverage - livemint.com Reports the ministry's findings and officials' statements without editorialising, and includes market projections from a government body. No framing favour or criticism of government action. This story was synthesised by AI from the source linked above. Tags: Central Drugs Standard Control Organization, Department of Health Research, Indian Council of Medical Research, Ministry of Health and Family Welfare Canonical: https://indianopinion.org/india-bars-routine-stem-cell-therapy-for-limb-ischemia-chronic-wounds/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/india-bars-routine-stem-cell-therapy-for-limb-ischemia-chronic-wounds/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/